EUVIMEDEUVIMED entdecken
Crossref

Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer

Wenhua Tang, Xiaoli Xu, Hang Hou, Chu Zhang, Wei Wei, Gui Chen, Liwen Zhang, Rui Chen, Yueping Shen, Mei Ji, Xin Yang iD

Small · 2025

DOI: 10.1002/smll.202504715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Wenhua Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Membrane Proteins, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Major Science and Technology Projects of Changzhou Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The STING pathway holds immunotherapeutic promise but faces challenges in tumor‐specific delivery and systemic toxicity. A lung‐targeting peptide (APWHLSAQYSRT)‐modified lipid nanoparticle (LNP) system (LT‐STING‐LNPs) is developed to deliver STING mRNA for non‐small cell lung cancer (NSCLC) treatment. These spherical, stable LNPs exhibited high mRNA encapsulation efficiency. In vitro, LT‐STING‐LNPs induced potent STING overexpression in lung cells, inhibiting NSCLC cell proliferation, migration, and invasion. In vivo, LNPs demonstrated superior lung tropism, enabling targeted STING activation in pulmonary tissue without systemic distribution. In murine lung metastasis models, treatment drastically reduced metastatic burden, suppressed tumor proliferation (Ki‐67), and inhibited epithelial‐mesenchymal transition (Vimentin). Notably, the platform shows excellent safety with no organ toxicity. LT‐STING‐LNPs synergized robustly with anti‐PD1 therapy, achieving near‐complete metastasis inhibition. Mechanistically, this is driven by STING‐TBK1‐IRF3 signaling activation, inflammatory cytokine (IFN‐α, IL‐1β, CXCL10) production, and immune microenvironment remodeling, including increased CD8+ T cell and M1 macrophage infiltration. This targeted, safe, and highly effective immunotherapy strategy represents a promising advancement for NSCLC, leveraging synergistic STING pathway activation and immune checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMembrane ProteinsNanoparticlesRNA, MessengerLungDisease ProgressionAnimalsHumansMiceCell Line, TumorCell ProliferationLiposomesSTING Protein

Stichwörter der Autor:innen

STINGanti‐tumor immunityimmune checkpoint inhibitorslung tissue‐targeting lipid nanoparticlesnon‐small cell lung cancer (NSCLC)

Substanzen

Membrane ProteinsRNA, MessengerLiposomesSTING1 protein, humanSTING ProteinLipid Nanoparticles

Autor:innen und Institutionen

  • Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China.
  • Department of Integrated Chinese and Western Medicine, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China.
  • Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, 199 Renai Road, Suzhou, 215123, China.

ORCID-Profile: Xin Yang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Major Science and Technology Projects of Changzhou Health Commission
  • Changzhou Science and Technology Project
  • Research Project on Emerging Supportive Therapy for Oncology
  • Beijing Bethune Charitable Foundation

Zitieren

APA

Tang, W., Xu, X., Hou, H., Zhang, C., Wei, W., Chen, G., Zhang, L., Chen, R., Shen, Y., Ji, M., & Yang, X. (2025). Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer. Small. https://doi.org/10.1002/smll.202504715

Vancouver

Tang W, Xu X, Hou H, Zhang C, Wei W, Chen G, et al. Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer. Small. 2025. doi:10.1002/smll.202504715

BibTeX
@article{Tang2025,
  author = {Tang, Wenhua and Xu, Xiaoli and Hou, Hang and Zhang, Chu and Wei, Wei and Chen, Gui and Zhang, Liwen and Chen, Rui and Shen, Yueping and Ji, Mei and Yang, Xin},
  title = {Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202504715}
}
Kostenlos starten →